Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Androgen Deprivation Therapy Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The androgen deprivation therapy market has witnessed substantial expansion in recent years. Its value is projected to climb from $8.31 billion in 2025 to $8.83 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.3%. Historically, this growth stemmed from conditions such as limited available treatment options for prostate cancer, a prevailing reliance on conventional surgical procedures, the gradual adoption of injectable therapies, insufficient patient awareness concerning androgen deprivation therapy, and constraints in the availability of advanced therapeutic methods.
The androgen deprivation therapy market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $11.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This anticipated growth can be linked to several factors, including the emergence of innovative anti-androgen medications, increased capital allocation towards gene and immunotherapies, a growing elderly male demographic, the expansion of specialized clinics and hospital oncology units, and the incorporation of digital oversight and telehealth services. Key developments expected during this forecast period involve the increased adoption of LHRH agonists and antagonists, greater utilization of combination and targeted treatments, the proliferation of minimally invasive surgical techniques, an intensified focus on personalized and age-appropriate patient care, and improved surveillance and follow-up protocols for individuals with prostate cancer.
Get A Free Sample Report With In-Depth Market Insights:
Androgen Deprivation Therapy Market Growth Factors: What’s Supporting Expansion?
The rising occurrence of prostate cancer is projected to propel the expansion of the androgen deprivation therapy market in the foreseeable future. This cancer develops in the prostate gland, an organ within the male reproductive system that produces seminal fluid. Its frequency is increasing, primarily attributable to extended life expectancies, given that advanced age notably elevates the likelihood of contracting the condition. Androgen deprivation therapy (ADT) serves as a key therapeutic approach for prostate cancer, designed to reduce androgen levels, which stimulate tumor proliferation. This treatment is commonly employed in advanced or metastatic stages to impede the advancement of the disease. For instance, a January 2025 report from Prostate Cancer UK, a UK-based organization focused on prostate cancer research, awareness, and support, revealed that in England, prostate cancer diagnoses grew from 50,751 cases in 2022 to 55,033 cases in 2023, showing a clear annual increase. Consequently, the rising prevalence of prostate cancer is driving the growth of the androgen deprivation therapy market.
Androgen Deprivation Therapy Market Segment Analysis: What Are The Core Market Categories?
The androgen deprivation therapy market covered in this report is segmented –
1) By Type: Medicine, Surgery, Other Types
2) By Route Of Administration: Injectable, Oral
3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75
4) By Application: Prostate Cancer, Other Applications
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies
2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy
3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU
Androgen Deprivation Therapy Market Industry Trends: What’s Reshaping Demand?
Leading firms within the androgen deprivation therapy (ADT) market are concentrating on creating sophisticated treatments, including oral androgen receptor inhibitors (ARIs), to offer more accessible, manageable, and potent therapeutic choices for individuals with prostate cancer. These oral ARIs represent targeted interventions designed to directly impede androgen receptor activity in prostate cancer cells, thereby inhibiting tumor progression without the necessity of regular, clinic-administered hormone-suppressing injections. A notable example occurred in June 2025, when Bayer AG, a Germany-based multinational pharmaceutical company, obtained US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide), an oral ARI prescribed alongside ADT for managing metastatic hormone-sensitive prostate cancer (mHSPC). Intended to enhance clinical results and patients’ quality of life, Nubeqa effectively curbs androgen receptor signaling due to its strong binding affinity, exhibits negligible blood–brain barrier penetration to mitigate central nervous system adverse effects, and demonstrated a 46% reduction in the likelihood of radiological progression or death when compared to a placebo combined with ADT, as confirmed by the Phase III ARANOTE trial.
Androgen Deprivation Therapy Market Top Companies Driving Competitive Growth
Major companies operating in the androgen deprivation therapy market are Johnson & Johnson Services Inc., Astellas Pharma Inc., Ipsen S.A., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Orion Corporation, Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Lawley Pharmaceuticals Pty Ltd., AbbVie Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Cipla Ltd., Accord Healthcare Ltd., Mylan N.V. (Viatris), Zydus Lifesciences Ltd., Apotex Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Alvogen Inc., BCN Peptides SA, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd.
View The Full Androgen Deprivation Therapy Market Report:
Androgen Deprivation Therapy Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the androgen deprivation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model